Table 2.
GLORIA registry baseline patient demographics and clinical characteristics.
| Characteristics | Mean (SD)a | ||
|---|---|---|---|
| Levodopa <2000 mg/day (n = 309) | Levodopa ≥2000 mg/day (n = 47) | Overall (N = 356) | |
| Age, years | 66.6 (8.4) | 66.6 (8.4) | 66.6 (8.4) |
| Sex, n (%) | |||
| Female | 132 (43) | 13 (28) | 145 (41) |
| Male | 177 (57) | 34 (72) | 211 (59) |
| Race, n (%) | |||
| White | 301 (99) | 43 (94) | 344 (98) |
| Asian | 2 (0.7) | 2 (4.3) | 4 (1.1) |
| Black/African American | 1 (0.3) | — | 1 (0.3) |
| American Indian/Alaska Native | 1 (0.3) | 1 (2.2) | 2 (0.6) |
| BMI, kg/m2 | 25.0 (4.0)b | 26.1 (6.2)c | 25.1 (4.4)d |
| Weight, kg | 70.5 (13.8)e | 73.7 (17.7)f | 70.9 (14.4)g |
| PD duration, years | 13.0 (6.5)h | 12.0 (4.7)i | 12.8 (6.3)j |
| Baseline oral levodopa dosage, mg/d | 876.9 (443.3)k | 1156.3 (418.3)l | 913.6 (449.5)m |
| UPDRS part II score | 16.1 (9.8)n | 17.8 (9.7)o | 16.3 (9.8)p |
| UPDRS part III score | 25.0 (12.2)q | 21.8 (10.2)r | 24.6 (12.0)s |
| Modified UPDRS part IV item 39 “Off” time, hours | 5.9 (3.0)t | 6.8 (3.9)u | 6.0 (3.2)v |
| Modified UPDRS part IV item 32 “On” time with TSD, hours | 4.5 (3.8)w | 3.3 (3.7)x | 4.3 (3.8)y |
| Previous PD treatment, n (%) | |||
| Oral levodopa | 269 (87) | 41 (87) | 310 (87) |
| Dopamine agonists | 256 (83) | 43 (92) | 299 (84) |
| COMT inhibitors | 204 (66) | 39 (83) | 243 (68) |
| MAO-B inhibitors | 154 (50) | 25 (53) | 179 (50) |
| Amantadine | 130 (42) | 18 (38) | 148 (42) |
| Others | 48 (16) | 10 (21) | 58 (16) |
aData are shown as mean (SD) except where indicated as n (%). bn: 219; cn: 34; dn: 253; en: 245; fn: 38; gn: 283; hn: 281; in: 47; jn: 328; kn: 304; ln: 46; mn: 350; nn: 200; on: 30; pn: 230; qn: 224; rn: 34; sn: 258; tn: 182; un: 29; vn: 211; wn: 187; xn: 28; yn: 217. BMI: body mass index; COMT: catechol-O-methyl transferase; MAO-B: monoamine oxidase; PD: Parkinson's disease; SD: standard deviation; TSD: troublesome dyskinesia; UPDRS: Unified Parkinson's Disease Rating Scale.